PRESS RELEASE Oncodesign announces the launch of its first clinical study on a radiotracer in patients with non-small cell lung cancer  First clinical study evaluating a mutated EGFR-receptor marker in patients using

First Page		Document Content
Date: 2016-07-12 12:51:48 Medicine Clinical medicine Tyrosine kinase receptors Quinazolines Epidermal growth factor receptor Oncogenes Targeted therapy Biomarker Treatment of cancer Positron emission tomography Imaging biomarker Erlotinib		PRESS RELEASE Oncodesign announces the launch of its first clinical study on a radiotracer in patients with non-small cell lung cancer  First clinical study evaluating a mutated EGFR-receptor marker in patients using Add to Reading List Source URL: www.oncodesign.com Download Document from Source Website File Size: 439,16 KB Share Document on Facebook

	AbstractProspective multicenter phase II study of the anti-EGFR (epidermal growth factor receptor) antibody panitumumab (P) in patients with platinum pre-treated, advanced head and neck squamous cell cancer (HNSCC DocID: 1rVAJ - View Document
	UNIVERSITÄTSKLINIKUM Schleswig-Holstein Immuntherapie des Glioblastoms Sampson et al. - Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor DocID: 1rgeq - View Document
	Abstract ErbB2 overexpression gives rise to a highly invasive, aggressive phenotype associated with an enlarged lysosomal compartment and increased activity of the lysosomal proteases, cysteine cathepsins. We have recent DocID: 1rdcC - View Document
	Wrangling Phosphoproteomic Data to Elucidate Cancer Signaling Pathways Mark L. Grimes1*, Wan-Jui Lee2, Laurens van der Maaten2, Paul Shannon3 1 Division of Biological Sciences, University of Montana, Missoula, Montana, U DocID: 1qMPs - View Document
	ZAI Lab and Hanmi execute a license agreement to develop novel EGFR targeted therapy for lung cancer in China Shanghai, China and Seoul, Korea, 23th November 2015 – ZAI Lab Limited and Hanmi Pharm. Co., Ltd. announced DocID: 1qm1i - View Document